{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T16:40:34Z","timestamp":1788280834554,"version":"build-2803163510"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2015,4,15]],"date-time":"2015-04-15T00:00:00Z","timestamp":1429056000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Pharmacokinet"],"published-print":{"date-parts":[[2015,9]]},"DOI":"10.1007\/s40262-015-0265-3","type":"journal-article","created":{"date-parts":[[2015,4,14]],"date-time":"2015-04-14T06:42:59Z","timestamp":1428993779000},"page":"975-984","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":25,"title":["Jejunal Infusion of Levodopa\u2013Carbidopa Intestinal Gel Versus Oral Administration of Levodopa\u2013Carbidopa Tablets in Japanese Subjects with Advanced Parkinson\u2019s Disease: Pharmacokinetics and Pilot Efficacy and Safety"],"prefix":"10.1007","volume":"54","author":[{"given":"Ahmed A.","family":"Othman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Krai","family":"Chatamra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed-Eslam F.","family":"Mohamed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandeep","family":"Dutta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janet","family":"Benesh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masayoshi","family":"Yanagawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masahiro","family":"Nagai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2015,4,15]]},"reference":[{"issue":"1","key":"265_CR1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1159\/000215875","volume":"62","author":"RA Hauser","year":"2009","unstructured":"Hauser RA. Levodopa: past, present, and future. Eur Neurol. 2009;62(1):1\u20138.","journal-title":"Eur Neurol"},{"issue":"3","key":"265_CR2","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1002\/mds.1090","volume":"16","author":"JE Ahlskog","year":"2001","unstructured":"Ahlskog JE, Muenter MD. Frequency of levodopa-related dyskinesias and motor fluctuations as estimated from the cumulative literature. Mov Disord. 2001;16(3):448\u201358.","journal-title":"Mov Disord"},{"issue":"2","key":"265_CR3","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1208\/s12248-012-9439-1","volume":"15","author":"D Nyholm","year":"2013","unstructured":"Nyholm D, Odin P, Johansson A, Chatamra K, Locke C, Dutta S, et al. Pharmacokinetics of levodopa, carbidopa, and 3-O-methyldopa following 16-h jejunal infusion of levodopa-carbidopa intestinal gel in advanced Parkinson\u2019s disease patients. AAPS J. 2013;15(2):316\u201323.","journal-title":"AAPS J."},{"issue":"Suppl","key":"265_CR4","doi-asserted-by":"crossref","first-page":"S13","DOI":"10.1016\/j.parkreldis.2007.06.005","volume":"13","author":"D Nyholm","year":"2007","unstructured":"Nyholm D. The rationale for continuous dopaminergic stimulation in advanced Parkinson\u2019s disease. Parkinsonism Relat Disord. 2007;13(Suppl):S13\u20137.","journal-title":"Parkinsonism Relat Disord."},{"issue":"1","key":"265_CR5","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1097\/00002826-198403000-00002","volume":"7","author":"JG Nutt","year":"1984","unstructured":"Nutt JG, Fellman JH. Pharmacokinetics of levodopa. Clin Neuropharmacol. 1984;7(1):35\u201349.","journal-title":"Clin Neuropharmacol"},{"issue":"6","key":"265_CR6","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1002\/mds.1203","volume":"16","author":"R Hardoff","year":"2001","unstructured":"Hardoff R, Sula M, Tamir A, Soil A, Front A, Badarna S, et al. Gastric emptying time and gastric motility in patients with Parkinson\u2019s disease. Mov Disord. 2001;16(6):1041\u20137.","journal-title":"Mov Disord"},{"issue":"3","key":"265_CR7","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1212\/WNL.38.3.419","volume":"38","author":"R Kurlan","year":"1988","unstructured":"Kurlan R, Rothfield KP, Woodward WR, Nutt JG, Miller C, Lichter D, et al. Erratic gastric emptying of levodopa may cause \u201crandom\u201d fluctuations of parkinsonian mobility. Neurology. 1988;38(3):419\u201321.","journal-title":"Neurology."},{"issue":"8","key":"265_CR8","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1056\/NEJM198402233100802","volume":"310","author":"JG Nutt","year":"1984","unstructured":"Nutt JG, Woodward WR, Hammerstad JP, Carter JH, Anderson JL. The \u201con-off\u201d phenomenon in Parkinson\u2019s disease. Relation to levodopa absorption and transport. N Engl J Med. 1984;310(8):483\u20138.","journal-title":"N Engl J Med"},{"issue":"5","key":"265_CR9","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1212\/WNL.44.5.913","volume":"44","author":"JG Nutt","year":"1994","unstructured":"Nutt JG, Woodward WR, Beckner RM, Stone CK, Berggren K, Carter JH, et al. Effect of peripheral catechol-O-methyltransferase inhibition on the pharmacokinetics and pharmacodynamics of levodopa in parkinsonian patients. Neurology. 1994;44(5):913\u20139.","journal-title":"Neurology."},{"issue":"5","key":"265_CR10","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1097\/01.wnf.0000144041.28224.b7","volume":"27","author":"D Nyholm","year":"2004","unstructured":"Nyholm D, Aquilonius SM. Levodopa infusion therapy in Parkinson disease: state of the art in 2004. Clin Neuropharmacol. 2004;27(5):245\u201356.","journal-title":"Clin Neuropharmacol."},{"issue":"3","key":"265_CR11","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1111\/j.1365-2125.1993.tb05691.x","volume":"35","author":"H Lennernas","year":"1993","unstructured":"Lennernas H, Nilsson D, Aquilonius SM, Ahrenstedt O, Knutson L, Paalzow LK. The effect of l-leucine on the absorption of levodopa, studied by regional jejunal perfusion in man. Br J Clin Pharmacol. 1993;35(3):243\u201350.","journal-title":"Br J Clin Pharmacol"},{"issue":"3","key":"265_CR12","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1097\/00002826-200305000-00010","volume":"26","author":"D Nyholm","year":"2003","unstructured":"Nyholm D, Askmark H, Gomes-Trolin C, Knutson T, Lennernas H, Nystrom C, et al. Optimizing levodopa pharmacokinetics: intestinal infusion versus oral sustained-release tablets. Clin Neuropharmacol. 2003;26(3):156\u201363.","journal-title":"Clin Neuropharmacol."},{"issue":"2","key":"265_CR13","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1212\/01.WNL.0000149637.70961.4C","volume":"64","author":"D Nyholm","year":"2005","unstructured":"Nyholm D, Nilsson Remahl AI, Dizdar N, Constantinescu R, Holmberg B, Jansson R, et al. Duodenal levodopa infusion monotherapy vs oral polypharmacy in advanced Parkinson disease. Neurology. 2005;64(2):216\u201323.","journal-title":"Neurology."},{"issue":"2","key":"265_CR14","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/S1474-4422(13)70293-X","volume":"13","author":"CW Olanow","year":"2014","unstructured":"Olanow CW, Kieburtz K, Odin P, Espay AJ, Standaert DG, Fernandez HH, et al. Continuous intrajejunal infusion of levodopa-carbidopa intestinal gel for patients with advanced Parkinson\u2019s disease: a randomised, controlled, double-blind, double-dummy study. Lancet Neurol. 2014;13(2):141\u20139.","journal-title":"Lancet Neurol"},{"key":"265_CR15","author":"HH Fernandez","year":"2014","unstructured":"Fernandez HH, Standaert DG, Hauser RA, Lang AE, Fung VSC, Klostermann F, et al. Levodopa-carbidopa intestinal gel in advanced Parkinson disease: final 12-month, open-label results. Mov Disord. 2014. doi: 10.1002\/mds.26123 .","journal-title":"Mov Disord"},{"issue":"1","key":"265_CR16","doi-asserted-by":"crossref","first-page":"165","DOI":"10.3233\/JPD-140456","volume":"5","author":"JT Slevin","year":"2015","unstructured":"Slevin JT, Fernandez HH, Zadikoff C, Hall C, Eaton S, Dubow J, et al. Long-term safety and maintenance of efficacy of levodopa-carbidopa intestinal gel: an open-label extension of the double-blind pivotal study in advanced Parkinson\u2019s disease patients. J Parkinsons Dis. 2015;5(1):165\u201374.","journal-title":"J Parkinsons Dis."},{"issue":"2","key":"265_CR17","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1097\/00002826-200003000-00003","volume":"23","author":"RA Hauser","year":"2000","unstructured":"Hauser RA, Friedlander J, Zesiewicz TA, Adler CH, Seeberger LC, O\u2019Brien CF, et al. A home diary to assess functional status in patients with Parkinson\u2019s disease with motor fluctuations and dyskinesia. Clin Neuropharmacol. 2000;23(2):75\u201381.","journal-title":"Clin Neuropharmacol."},{"key":"265_CR18","unstructured":"Abbott Japan Co., Ltd. Study of safety, tolerability, pharmacokinetics, and efficacy of ABT-SLV187 in subjects with advanced Parkinson\u2019s disease [ClinicalTrials.gov identifier NCT01479127]. US National Institutes of Health, ClinicalTrials.gov. http:\/\/www.clinicaltrials.gov . Accessed 18 Mar 2015."},{"issue":"1","key":"265_CR19","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1111\/bcp.12324","volume":"78","author":"AA Othman","year":"2014","unstructured":"Othman AA, Dutta S. Population pharmacokinetics of levodopa in subjects with advanced Parkinson\u2019s disease: levodopa-carbidopa intestinal gel infusion vs. oral tablets. Br J Clin Pharmacol. 2014;78(1):94\u2013105.","journal-title":"Br J Clin Pharmacol"},{"issue":"11 Suppl 2","key":"265_CR20","first-page":"25","volume":"39","author":"KC Yeh","year":"1989","unstructured":"Yeh KC, August TF, Bush DF, Lasseter KC, Musson DG, Schwartz S, et al. Pharmacokinetics and bioavailability of Sinemet CR: a summary of human studies. Neurology. 1989;39(11 Suppl 2):25\u201338.","journal-title":"Neurology."},{"issue":"5","key":"265_CR21","doi-asserted-by":"crossref","first-page":"350","DOI":"10.2165\/00003088-199120050-00002","volume":"20","author":"AJ Wood","year":"1991","unstructured":"Wood AJ, Zhou HH. Ethnic differences in drug disposition and responsiveness. Clin Pharmacokinet. 1991;20(5):350\u201373.","journal-title":"Clin Pharmacokinet"},{"issue":"6","key":"265_CR22","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1038\/clpt.1984.116","volume":"35","author":"L Rivera-Calimlim","year":"1984","unstructured":"Rivera-Calimlim L, Reilly DK. Difference in erythrocyte catechol-O-methyltransferase activity between Orientals and Caucasians: difference in levodopa tolerance. Clin Pharmacol Ther. 1984;35(6):804\u20139.","journal-title":"Clin Pharmacol Ther"},{"key":"265_CR23","unstructured":"AbbVie. A study to assess the efficacy, safety and tolerability of ABT-SLV187 monotherapy in subjects with advanced Parkinson\u2019s disease (PD) and persistent motor complications, despite optimized treatment with available anti-parkinsonian medications [ClinicalTrials.gov identifier NCT01960842]. US National Institutes of Health, ClinicalTrials.gov. http:\/\/www.clinicaltrials.gov . Accessed 18 Mar 2015."}],"container-title":["Clinical Pharmacokinetics"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40262-015-0265-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40262-015-0265-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40262-015-0265-3","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,8,31]],"date-time":"2020-08-31T21:30:27Z","timestamp":1598909427000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40262-015-0265-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,4,15]]},"references-count":23,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2015,9]]}},"alternative-id":["265"],"URL":"https:\/\/doi.org\/10.1007\/s40262-015-0265-3","relation":{},"ISSN":["0312-5963","1179-1926"],"issn-type":[{"value":"0312-5963","type":"print"},{"value":"1179-1926","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,4,15]]}}}